Spruce Biosciences - SPRB Quarterly EPS earnings growth

Spruce Biosciences Inc. - graphic logo of issuer SPRB

Spruce Biosciences (SPRB) relies on the success of tildanserpone trials and patent protection. However, business development is constrained by R&D expenses and adrenal cortex test results. The quarterly EPS growth trend visualizes these factors, where 42.20 shows the current volume of the metric. Orphan drug status allows the company to exercise pricing power by setting premium prices for exclusive therapies for rare endocrine pathologies.

Spruce Biosciences (SPRB) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 11/14/2026

Financial and market metric breakdowns for Spruce Biosciences Inc. (SPRB)

- share price and consensus valuation forecast:
Stock Quotes Spruce Biosciences, Inc.|SPRB - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Spruce Biosciences|SPRB - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Spruce Biosciences|SPRB - Company Book Value|Market Value to Book Value Ratio sprucebiosciences.com|SPRB - Company Assets
- debt and liquidity data:
Debt to Equity Spruce Biosciences|SPRB - Long-Term Debt to Equity|Short-Term Debt to Capital Spruce Biosciences|SPRB - Company Total Debt Obligations|Debt to Book Capitalization Ratio Spruce Biosciences|SPRB - Long-Term Debt Volume|Company Short-Term Debt Spruce Biosciences|Quick Liquidity sprucebiosciences.com
- earnings and valuation multiples indicators:
SPRB - Net Financial Result|Expected Profit Spruce Biosciences|SPRB - Market Cap to Net Income|Future Price to Earnings Spruce Biosciences, Inc.|SPRB - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Spruce Biosciences|SPRB - Operating profit EBITDA|Net earnings per share (EPS TTM) Spruce Biosciences|SPRB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth sprucebiosciences.com|SPRB - Earnings per share growth rate in current year|Expected earnings per share growth for next year Spruce Biosciences
- sales volume and revenue information:
SPRB - Company Sales Revenue|Projected Sales Volume Spruce Biosciences|SPRB - Price-to-Revenue Ratio|Forward P/S Multiple Spruce Biosciences
Analysis of all company metrics:Spruce Biosciences
Manufactured product of Spruce Biosciences Inc.

From a portfolio manager's perspective, this indicator reflects the rate of change in earnings per share, allowing for an assessment of business capitalization efficiency over the short term. By analyzing the quarterly earnings per share growth chart, an investor can see how the precision of Spruce Biosciences (SPRB) clinical developments in endocrinology converts into actual financial results and accelerated returns for the issuer.

Competitors of Spruce Biosciences (SPRB)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Corp|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (metsera.com)|Year-over-year earnings per share growth for the last twelve months MoonLake MLTX|Crinetics Pharmaceuticals, Inc. (CRNX) - Earnings per share growth in annualized terms for the last twelve months|NAMS - Year-over-year earnings per share growth for the last twelve months|SLNO: Year-over-year earnings per share growth for the last twelve months|FOLD: Quarterly EPS earnings growth|ETNB - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Agios Pharmaceuticals, Inc.|Structure Therapeutics Inc (GPCR) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months MiMedx Group (MDXG)|Year-over-year net earnings per share growth for the last 12 months Rezolute Bio RZLT|Year-over-year earnings per share growth for the last twelve months Lexicon Pharmaceuticals LXRX|Year-over-year net earnings per share change for the last twelve months mbxbio.com (MBX)|ALT - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months AARD|Sagimet (SGMT) - Year-over-year earnings per share growth for the last twelve months|BioAge Labs, Inc - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months BMEA|Quarterly EPS earnings growth Quince|Quarterly EPS earnings growth GUTS|Year-over-year net earnings per share growth for the last 12 months vtvtherapeutics.com VTVT|Quarterly EPS earnings growth ATPC (Agape ATP)|Pluristem Therapeutics (PLUR) - Earnings per share growth in annualized terms for the last twelve months|SYBX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months LPCN (lipocine.com)|MTNB: Quarterly EPS earnings growth|GLTO (Galecto Inc) - Year-over-year earnings per share growth for the last twelve months|CTCX (Carmell Corp) - Quarterly EPS earnings growth|Lumos Therapeutics (LUMO) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Organovo Holdings, Inc. (ONVO)|RDUS - Earnings per share growth in annualized terms for the last twelve months